Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease

Current Hypertension Reports

Volumn 4, Issue 2, 2002, Pages 93-95

  Chobanian, Aram V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN RECEPTOR; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PYRIDINE DERIVATIVE;

ANIMAL; ARTERY; ARTICLE; BLOOD PRESSURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; VASCULAR DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ANIMALS; ARTERIES; BLOOD PRESSURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RISK FACTORS; VASCULAR DISEASES;

EID: 0036549168     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-002-0030-5     Document Type: Note

References (28)

1. Working Group on Management of Patients With Hypertension and High Blood Cholesterol: National Educational Program Working Group report on the management of patients with hypertension and high blood cholesterol. Ann Intern Med 1991, 114:224-237.
2. Chobanian AV, Alexander RW: Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Arch Intern Med 1996, 156:1952-1956.
3. Kim JA, Berliner JA, Nadler JL: Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun 1996, 226:862-868.
4. Capers Q, Alexander RW, Lou P, et al: Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997, 30(6):1397-1402.
5. Feener EP, Northrup JM, Aiello L.P., King GL: Angiotensin induces plasminogen activator inhibitor -1 and -2 expression in vascular endothelial and small muscle cells. J Clin Invest 1995, 95:1353-1362.
6. Chobanian AV, Haudenschild CC, Nickerson C, Drago R: Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990, 15:327-331.
7. Aberg G, Ferrer P: Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990, 15:S65-S72.
8. Hope S, Brecher P, Chobanian AV: Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens 1999, 12:28-34.
9. Strawn WB, Chappell MC, Dean R.H., et al.: Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000, 101: 1586-1593.
10. Keidar S, Attias J, Smith J., et al.: The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 1997, 236:622-625.
11. Williams JK, Sukhova GK, Herrington D.M., Libby P: Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998, 31: 684-691.
12. Hernandez-Presa M., Bustos C, Ortego M., et al.: Angiotensinconverting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997, 95:1532-1541.
13. Weber C, Erl W, Weber K.S., Weber PC: HMG-CoA reductase inhibitors decrease CD 11 B expression and CD 11 Bdependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesteorlemia. J Am Coll Cardiol 1997, 30:1212-1217.
14. Negre-Aminou P., van Vliet AK, van Erck M, et al: Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochimica et Biophysica Acta 1997, 1345:259-268.
15. Isaacsohn JL, Setaro JF, Nicholas C, et al: Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol 1994, 74:735-737.
16. Ridker PM, Cushman M, Stampfer M.J., et al.: Inflammation, aspirin, and risks of cardiovascular disease in apparently health men. N Engl J Med 1997, 336:973-979.
17. Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97:2007-2011.
18. Ridker PM, Rifer N, Pfeffer M.A., et al, for the Cholesterol and Recurrent Events (CARE) Investigators: Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999, 100:230-235.
19. Kranzhöfer R., Schmidt J, Pfeiffer CAH, et al.: Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999, 19:1623-1629.
20. Dechend R, Fiebler A, Lindschau C., et al.: Modulating angiotensin II-induced inflammation by HMG-CoA reductase inhibition. Am J Hypertens 2001, 14:55S-61S.
21. Luo JD, Zhang WW, Zhang G.P., et al.: Simvastatin inhibits cardiac hypertrophy and angiontensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999, 11:903-908.
22. Scheidegger KJ, Butler S, Witzum JL: Angiotensin II increases macrophage mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem 1997, 272:21609-21615.
23. Nickenig G, Sachinidis A, Michaelson F., et al.: Upregulation of vascular angiotensin II receptor gene expression by low density lipoprotein in vascular smooth muscle cells. Circulation 1997, 95:473-478.
24. Nickenig G, Jung O, Strehlow K., et al.: Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol 1997, 272:H2701-H2707.
25. Yang BC, Phillips I, Mohuczy D., et al.: Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998, 18:1433-1439.
26. Nickenig G, Bäumer AT, Temur Y., et al.: Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100:2131-2134.
27. Glorioso N, Troffa C, Filigheddu F., et al.: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34:1281-1286.
28. Grimm RH J.r., Margolis KL, Papademetriou V, et al: Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2001, 37:19-27.